A review in Proceedings of the National Academy of Sciences noted that "multiple large case-control studies have reported positive associations between high circulating levels of IGF-I and risk for different types of cancer," including breast, colorectal, and prostate cancers
Administration should only be performed by trained healthcare professionals in a clinical environment, ensuring safety and efficacy throughout the process
1 Adverse reactions that occurred in 2% of patients treated with RADICAVA and 2% more frequently in placebo-treated patients 1 Hypersensitivity reactions and cases of anaphylaxis have been reported in postmarketing reports with RADICAVA 1 Discontinuations were not associated with contusion, gait disturbance, or headache in patients treated with RADICAVA 2 No known drug interactions based on in vitro drug interaction studies 1 RADICAVA ORS Was Generally Well Tolerated 1,3 The safety profile of RADICAVA ORS was demonstrated in a 6-month, phase 3, open-label clinical trial in 185 patients
Research peptides sold online are not regulated for purity, dosing accuracy, or sterility, carrying substantial risks
